Research Article

P3H4 Overexpression Serves as a Prognostic Factor in Lung Adenocarcinoma

Xiangfeng Jin, Haiqing Zhou, Jianfang Song, Hong Cui, Yiren Luo, and Haiping Jiang

1Department of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province 266003, China
2Department of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province 266003, China
3Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province 266003, China
4Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province 266003, China

Correspondence should be addressed to Yiren Luo; qdlyr@163.com and Haiping Jiang; jhaiping@163.com

Received 8 March 2021; Revised 28 May 2021; Accepted 3 June 2021; Published 24 June 2021

Copyright © 2021 Xiangfeng Jin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The present study is aimed at evaluating the functional and clinical values of P3H4 in lung adenocarcinoma. Moreover, we also investigated the downstream pathways that P3H4 might participate in. Methods. The differential expression analysis was used to identify genes differentially expressed in lung adenocarcinoma tissues as compared with normal tissues. Survival analysis was used to test the association between P3H4 and survival time. Gene set enrichment analysis was conducted to explore the downstream pathways. CCK8 and transwell were employed to examine the impact of P3H4 on cell phenotypes. Results. P3H4 was highly upregulated in LUAD tissues at both RNA and protein levels. Moreover, the LUAD patients, who had high expression of P3H4, were also observed to have shorter disease-free survival and overall survival. These results demonstrated that P3H4 could be used as a prognostic biomarker for LUAD. Moreover, we also found that it was the copy number alterations (CNAs), not DNA methylation, that regulated the RNA expression of P3H4, indicating that its upregulation might be partially resulted from the CNAs. Furthermore, functional experiments revealed that the A549 and H1299 cells with siRNA treatment (siP3H4) exhibited significantly decreased cell proliferation after 24 hours, migratory ability, and invasiveness. Functionally, the upregulated proteins in the P3H4 high expression group were mainly enriched in tumor microenvironment-related pathways such as phagosome, focal adhesion, and ECM-receptor interaction and cancer-related pathways such as bladder cancer pathway, proteoglycans in cancer, and hippo signaling pathway. Conclusion. The present study systematically evaluated the functional and clinical values of P3H4 in LUAD, and explored the related biological pathways. P3H4 might promote LUAD progression through regulating tumor microenvironment-related pathways.

1. Introduction

Lung adenocarcinoma (LUAD) is a major type of non-small-cell lung cancers (NSCLC) [1]. Developed in the epithelial cells of the lung, it is also the most common type of lung cancer, which accounts for nearly 40% of all lung cancer cases [2]. Compared to the other subtypes of lung cancers, lung adenocarcinoma is less aggressive, and favorable prognoses are observed in patients with small, localized adenocarcinoma (stage I) [3]. However, most patients with LUAD are diagnosed at advanced stages, where metastasis has occurred, which leads to a disheartening survival rate [4, 5].

Tumor microenvironment (TME) and the organization of local extracellular matrix (ECM) are found to be essential players in tumor progression and metastasis in various cancers [6–8]. The crosstalk between tumor cells and the immune cells modulates multiple aspects of tumorigenesis, and targeting important pathways in TME is considered a promising therapeutic strategy [9]. Also, tumor-associated macrophages (TAMs), which are an abundant cell
population in the TME, could regulate the expression of immunosuppressive molecules such as PD-L1 and phagocytosis inhibitors, thereby promoting tumor progression and resistance to therapy [10].

Prolyl 3-hydroxylase (P3H) is a rare but conserved posttranslational modification in many collagen types [11] and may be implicated in a tumor microenvironment [12]. Specifically, two members of P3H genes, P3H2 and P3H3, are identified as novel targets for epigenetic silencing in breast cancer [13]. In bladder cancer, knockdown of P3H4 would result in arrested cell cycle and decreased expression levels of EMT-related proteins, suggesting that silence of P3H4 could efficiently inhibit the uncontrolled proliferation and invasiveness of bladder cancer [14]. Also, an association between increased P3H4 expressions and the high pathological stage and worse survival has been observed in bladder cancer [15]. Moreover, P3H4 is inferred from sequence similarity to be in a complex essential for cross-linking of collagen fibrils, and collagen cross-linking is reported to increase tumor cell proliferation and promote metastasis [16, 17].

Herein, we conducted a systematic analysis of P3H4 in tumor tissues at both RNA and protein levels and demonstrated its impact on cancer cell functionalities, anticipating to shed light on the potential function and mechanism of P3H4 in LUAD.

2. Materials and Methods

2.1. Gene Expression Data Collection. The gene expression dataset was obtained from public databases including UCSC Xena (https://xena.ucsc.edu/) with accession numbers: TCGA-LUAD [18], The Fragment Per Kilo Million (FPKM-) based gene expression was calculated for RNA sequencing data, respectively. In brief, the reads were aligned to human reference genome by STAR v2 [19], and gene expression levels were measured by HTSeq [20]. The protein expression data of LUAD and adjacent normal tissues were collected from LinkedOmics (http://linkedomics.org).

2.2. Differential Expression Analysis. The differential gene expression levels were tested by Student’s t-test and fold change method. The P values by Student’s t-test was adjusted by the Bonferroni method. The genes, which had adjusted P value < 0.05 and fold change > 2, were identified as dysregulated genes.

2.3. Survival Analysis. The univariable Cox regression model was built to evaluate the association between P3H4 expression levels and LUAD survival time. The samples were stratified into the high and low P3H4 expression groups using the median expression of P3H4 as the cutoff. The statistical significance of the association of P3H4 with survival time was evaluated by a log-rank test. The survival analysis was implemented in R survival package [21].

2.4. The Gene Set Analysis. The overrepresentation enrichment analysis (ORA) was used to identify the Reactome pathways enriched by the upregulated genes [22]. The enrichment degree of the ribosomal proteins in the genes highly correlated with P3H4 was tested by gene set enrichment analysis (GSEA). The ORA was implemented in R clusterProfiler package [23].

2.5. Cell Culture and Transfection. The two human lung cancer cell lines (A549 and H1299) were purchased from Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS). These cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (Gibco) and 1% penicillin-streptomycin and incubated at 37°C with 5% CO₂. The two small-interface RNAs specifically binding P3H4 mRNA and the negative control were denoted as si-P3H4-1, si-P3H4-2, and si-NC. The transfection was conducted on the cells in logarithmic phase using Lipofectamine 2000 (Thermo Fisher Scientific). The following are the sequences of siRNAs: si-P3H4-1—GGGCUGUGAAGCUC UACAAAC; si-P3H4-2—GGCACGCUCCUGAGCAGUAG.

2.6. Real-Time Reverse Transcription PCR. Total RNAs from A549 and H1299 cells were separated using a TRIzol reagent. Following the manufacturer’s protocol, we performed the reverse transcription using PrimeScript RT reagent kit (TaKaRa, Tokyo, Japan). P3H4 mRNA expression was quantitatively analyzed using an ABI Prism 7900HT (Applied Biosystems, Foster City, CA), with GAPDH as an internal reference. The following are the primers for P3H4: forward—5'-CATGAGCACGTTGACCTCAAGG-3', reverse—5'-ACTTGTCCACGAAGTGACC-3'; and the primers for GAPDH: forward—5'-AGGCTGTGGGG AAATCTTCC-3', reverse—5'-ACTGTTGAACCTCGGA ATGC-3'. All these experiments were conducted in triplicate.

2.7. Cell Counting Kit-8 (CCK8) Assay. The CCK8 assays were used to detect the cell proliferation. The experiments were conducted in 96-well plates with 2 × 10⁴ cells/well. Using a microplate reader (Bio-Rad, Shanghai, China), we detected the absorbance at 450 nm following the manual. All these experiments were conducted in triplicate.

2.8. Transwell Assay. The transwell chambers (8 µm pore size; Millipore) and chambers coated with Matrigel were used to conduct cell migration and invasion assays, respectively. The cells (5 × 10⁴ cells) with 48 h of transfection were planted into the upper chamber, and 500 µl of medium containing 10% FBS was filled into the lower chambers. The migrated or invaded cells with 4% paraformaldehyde, which were incubated at 37°C for 24 h, were fixed for 30 min and stained with 0.1% crystal violet for another 20 min. All these experiments were conducted in triplicate.

2.9. Statistical Analyses. The multiple-sample and two-sample comparisons were tested by the analysis of variance (ANOVA) and Student’s t-test in R language. The data are visualized as the mean value and 95% confidence interval. The hypothesis tests, which had P value < 0.05, were considered statistically significant.
3. Results

3.1. The mRNA Expression of P3H4 Is Highly Upregulated in Lung Adenocarcinoma Tissues. To investigate the RNA expression levels of P3H4 in lung adenocarcinoma (LUAD) and normal tissues, we compared its expression of LUAD with that of normal tissues using The Cancer Genome Atlas (TCGA) LUAD cohort. Specifically, P3H4 RNA expression was highly upregulated in LUAD (Figure 1(a), Wilcoxon rank sum test, \( P \) value < 0.001), with about 2-fold than the normal tissues. The survival analysis revealed that shorter overall survival was observed in samples with high mRNA expression of P3H4 as compared with those with low mRNA expression (Figure 1(b), \( P \) value < 0.05).

To further explore the transcription of P3H4, we investigated whether the copy number alteration (CNAs) and DNA methylation levels were associated with its RNA expression. The Pearson correlation between the DNA methylation and RNA expression of P3H4 was about -0.081, suggesting that P3H4 mRNA expression was poorly associated with DNA methylation (Figure 1(c), \( P \) value = 0.072). Moreover, the comparison of P3H4 RNA expression between the tumor samples with P3H4 gain and those without P3H4 gain revealed that P3H4 was expressed higher in those with P3H4 gain (Figure 1(d), \( P \) value < 0.001). These results indicated that P3H4 was highly upregulated in LUAD tissues and its upregulation might be partially resulted from the CNAs.

3.2. Validation of High P3H4 Expression in LUAD at Protein Level. As P3H4 was highly upregulated in LUAD at the RNA level, we then examined its protein expression using mass spectrum proteomics data from Xu et al. [24]. Consistently,
the protein expression of P3H4 was also upregulated in LUAD as compared with the normal tissues (Figure 2(a), P value < 0.001). The further survival analysis of the P3H4 protein expression confirmed that P3H4 protein expression was also highly associated with both disease-free survival (DFS) and overall survival (OS) (Figure 2(b), log-rank test, P value < 0.05), suggesting that P3H4 protein expression was an indicator of poor prognosis in LUAD. To test the independence of P3H4 expression about the prediction of survival in LUAD, we conducted multivariable Cox regression analysis using TNM stage, age, and differentiation levels as cofactors. Remarkably, the P3H4 protein expression was also statistically significant in the multivariable Cox model (Figure 2(c)), suggesting that P3H4 protein expression was an independent prognostic factor in LUAD. These results further indicated that P3H4 was highly upregulated and might serve as an independent prognostic factor in LUAD.

3.3. Silence of P3H4 Inhibits Lung Cancer Cell Proliferation. To explore whether P3H4 regulated the functionalities of lung cancer cells, we silenced the P3H4 gene by two small interface RNAs (siRNAs) using A549 and H1299 cell lines. Specifically, the RNA expression levels of P3H4 were significantly suppressed by the siRNAs (Figures 3(a) and 3(b), P value < 0.05), indicating that this siRNA could efficiently decrease the P3H4 RNA expression. Compared with the negative control (siNC), the two cell lines with siRNAs treatment (si-P3H4-1 and si-P3H4-2) exhibited significantly decreased cell proliferation (Figures 3(c) and 3(d), P value < 0.05), suggesting that P3H4 gene silence could suppress the uncontrolled proliferation of A549 and H1299 cells.

3.4. Silence of P3H4 Inhibits Lung Cancer Cell Invasion and Migration. Furthermore, we also detected the impact of P3H4 silence on cancer cell migration and invasion. Specifically, transwell assay revealed that knockdown of P3H4 could significantly suppress the invasiveness of A549 and H1299 cell lines (Figures 4(a) and 4(b)). Furthermore, the decreased migratory ability of A549 and H1299 with P3H4 silence was also observed by the transwell assay (Figures 4(c) and 4(d)). These results indicated that P3H4 silence could significantly inhibit lung cancer cell invasion and migration.

3.5. P3H4-Related Signaling Pathways. To further explore the biological function of P3H4 protein in LUAD, the tumor samples of the proteome cohort were stratified into the high and low P3H4 expression groups. The differential expression analysis identified 305 upregulated and 11 downregulated proteins (Supplementary Table S1, adjusted P value < 0.05 and fold change > 2). Notably, only the upregulated proteins
were successfully enriched in the KEGG pathways by gene set enrichment analysis, as the number of downregulated proteins was small. Specifically, the upregulated proteins in the high P3H4 protein expression group were mainly enriched in the pathways regulating the tumor microenvironment such as phagosome, focal adhesion, and ECM-receptor interaction and cancer-related pathways such as bladder cancer pathway, proteoglycans in cancer, and hippo signaling pathway (Figure 5(a)). The network visualization of the pathways and related genes showed that FLNC, PLAU, WNT5A, THBS1, MSR1, FRMD6, PLAU, MMP2, DAPK3, AKT3, THBS2, TUBB2B, GPC1, MMP1, WWTR1, PDGFRA, RASSF2, THBS3, C1R, MRC2, COMP, and ITGA11 were the hub genes involved in these cancer or tumor microenvironment-related pathways (Figure 5(b)). These results indicated that P3H4 might promote LUAD progression through regulating cancer and tumor microenvironment-related pathways.

4. Discussion

In this study, in order to investigate the expression pattern and clinical values of P3H4 in lung adenocarcinoma, we conducted differential expression analysis and survival analysis on both TCGA and proteome cohort. Specifically, P3H4 was highly upregulated in LUAD tissues at both RNA and protein levels. Moreover, the LUAD patients, who had high expression of P3H4, were also observed to have shorter disease-free survival and overall survival. These results demonstrated that P3H4 could be used as a prognostic biomarker for LUAD. Notably, P3H4 was also observed to be closely associated with the prognosis of bladder cancer [15, 25]. As the cancer was initiated by genomic and epigenomic alterations like CNAs and abnormal DNA methylation [26, 27], we investigated the regulation of P3H4 by genomic and epigenomic alterations. The comparative analysis and correlation analysis revealed that it was the CNAs, not DNA methylation, that regulated the RNA expression of P3H4, indicating that its upregulation might be partially resulted from the CNAs. As the DNA is more stable with respect to RNA, the relative copy numbers of P3H4 might be used to evaluate P3H4 expression levels and patients’ risk using tumor tissues or circulating tumor cells (CTC) [28].

As P3H4 was highly expressed in LUAD, we then explored whether the functionalities of lung cancer cells could be significantly altered by silencing P3H4. Specifically, compared with the negative control (siNC), the cells with siRNA treatment (siP3H4) exhibited significantly decreased cell proliferation, migratory ability, and invasiveness using...
Figure 4: The impact of P3H4 silence on migratory and invasive abilities of A549 and H1299 cells. The cell invasion (a, b) and migration (c, d) of the siNC, siP3H4-1, and siP3H4-2 groups were detected and compared by transwell assays. The relative number of invaded and migratory cells is visualized as a bar plot on the right panel.
A549 and H1299 cell lines. Consistently, the inhibition of proliferation and invasion by the knockdown of P3H4 were also observed in bladder cancer [14].

Functionally, we also explored the biological function of P3H4 protein in LUAD. The upregulated proteins in the P3H4 high expression group were mainly enriched in tumor microenvironment-related pathways such as phagosome, focal adhesion, and ECM-receptor interaction and cancer-related pathways such as bladder cancer pathway, proteoglycans in cancer, and hippo signaling pathway. Notably, the molecules localizing to the extracellular matrix such as ITGA11, PDGFRA, THBS1/2/3, and COMP were coexpressed with P3H4 and might be the direct target of P3H4. ITGA11 was found to enhance tumorigenicity of human non-small-cell lung cancer cells by regulating IGF2 expression in fibroblasts [14]. PDGFRA is a famous growth factor receptor and has been widely reported to transfer signaling in various cancers [29, 30]. The thrombospondins (TSPs) are multifaced proteins and serve as important components of the tumor microenvironment [31], indicating that P3H4 might be a regulator of tumor microenvironment. Consistently, previous studies also found that P3H4 was involved in regulating the tumor microenvironment and implicated in sensitivity to targeted therapy and immunotherapy [12, 32].

In conclusion, the present study systematically evaluated the expression levels and clinical values of P3H4 in LUAD and explored the related biological pathways. P3H4 might promote LUAD progression through regulating tumor microenvironment-related pathways.

**Data Availability**

The datasets used and/or analyzed during the current study are available from public databases including TCGA and...
GEO, which have been cited as references in Materials and Methods.

**Consent**

All authors have agreed to publish this manuscript.

**Conflicts of Interest**

The authors declare that they have no competing interests.

**Authors’ Contributions**

Haiping Jiang and Yiren Luo conceived and designed the experiments. Xiangfeng Jin and Haiqing Zhou acquired the data, related materials, and analysis tools. Xiangfeng Jin conducted the experiments and analyzed the data. Xiangfeng Jin and Hong Cui wrote the paper. All authors read and approved the final manuscript.

**Acknowledgments**

We acknowledge the contribution of all investigators at all participating study sites.

**Supplementary Materials**

Supplementary Table S1: the differentially expressed genes between tumor samples with high and low P3H4 expression. (Supplementary Materials)

**References**

[1] J. N. Bodor, V. Kasireddy, and H. Borghaei, “First-line therapies for metastatic lung adenocarcinoma without a driver mutation,” Journal of Oncology Practice/ American Society of Clinical Oncology, vol. 14, no. 9, pp. 529–535, 2018.

[2] T. V. Denisenko, I. N. Budkevich, and B. Zhivotovsky, “Cell death-based treatment of lung adenocarcinoma,” Cell Death & Disease, vol. 9, no. 2, p. 117, 2018.

[3] K. Jao, P. Tomasini, S. Kamel-Reid et al., “The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer,” Lung Cancer, vol. 123, pp. 22–29, 2018.

[4] S. Blandin Knight, P. A. Crosbie, H. Balata, J. Chudziak, T. Hussell, and C. Dive, “Progress and prospects of early detection in lung cancer,” Open Biology, vol. 7, no. 9, 2017.

[5] J. J. Lin, S. Cardarella, C. A. Lydon et al., “Five-year survival in _EGFR_ -mutant metastatic lung adenocarcinoma treated with EGFR-TKIs,” Journal of Thoracic Oncology, vol. 11, no. 4, pp. 556–565, 2016.

[6] A. Dongre and R. A. Weinberg, “New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer,” Nature Reviews. Molecular Cell Biology, vol. 20, no. 2, pp. 69–84, 2019.

[7] D. C. Hinshaw and L. A. Shevde, “The tumor microenvironment innately modulates cancer progression,” Cancer Research, vol. 79, no. 18, pp. 4557–4566, 2019.

[8] A. G. Hawkins, V. Basrur, F. da Veiga Leprevost et al., “The Ewing sarcoma secretome and its response to activation of Wnt/beta-catenin signaling,” Molecular & Cellular Proteomics, vol. 17, no. 5, pp. 901–912, 2018.

[9] L. Hui and Y. Chen, “Tumor microenvironment: sanctuary of the devil,” Cancer Letters, vol. 368, no. 1, pp. 7–13, 2015.

[10] Y. Tian, M. Lu, W. Yue et al., “TGFBR-related factor 2 is associated with poor prognosis of nonsmall cell lung cancer patients through promoting tumor epithelial-mesenchymal transition,” BioMed Research International, vol. 2014, Article ID 530786, 13 pages, 2014.

[11] D. M. Hudson and D. R. Eyre, “Collagen prolyl 3-hydroxylation: a major role for a minor post-translational modification?,” Connective Tissue Research, vol. 54, no. 4–5, pp. 245–251, 2013.

[12] Y. W. Lim, G. L. Coles, S. K. Sandhu, D. S. Johnson, A. S. Adler, and E. L. Stone, “Single-cell transcriptomics reveals the effect of PD-1/L1/TGF-β blockade on the tumor microenvironment,” BMC Biology, vol. 19, no. 1, p. 107, 2021.

[13] R. Shah, P. Smith, C. Purdie et al., “The prolyl 3-hydroxylases P3H2 and P3H3 are novel targets for epigenetic silencing in breast cancer,” British Journal of Cancer, vol. 100, no. 10, pp. 1687–1696, 2009.

[14] L. Hao, K. Pang, H. Pang et al., “Knockdown of P3H3 inhibits proliferation and invasion of bladder cancer,” Aging, vol. 12, no. 3, pp. 2156–2168, 2020.

[15] Z. Chen, G. Liu, A. Hossain et al., “A co-expression network for differentially expressed genes in bladder cancer and a risk score model for predicting survival,” Hereditas, vol. 156, no. 1, p. 24, 2019.

[16] M. E. Heard, R. Besio, M. Weis et al., “Ses5-null mice provide evidence for a novel endoplasmic reticulum complex regulating collagen lysyl hydroxylation,” PLoS Genetics, vol. 12, no. 4, article e1006002, 2016.

[17] T. R. Cox, D. Bird, A. M. Baker et al., “LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis,” Cancer Research, vol. 73, no. 6, pp. 1721–1732, 2013.

[18] F. Farshidfar, S. Zheng, M. C. Gingras et al., “Integrative genomic analysis of cholangiocarcinoma identifies distinct _IDH_ -mutant molecular profiles,” Cell Reports, vol. 18, no. 11, pp. 2780–2794, 2017.

[19] A. Dobin, C. A. Davis, F. Schlesinger et al., “STAR: ultrafast universal RNA-seq aligner,” Bioinformatics, vol. 29, no. 1, pp. 15–21, 2013.

[20] S. Anders, P. T. Pyl, and W. Huber, “HTSeq—a Python framework to work with high-throughput sequencing data,” Bioinformatics, vol. 31, no. 2, pp. 166–169, 2015.

[21] J. C. A. Li, “Book reviews,” Sociological Methods & Research, vol. 32, no. 1, pp. 117–120, 2003.

[22] G. Yu and Q. Y. He, “ReactomePA: an R/bioconductor package for reactome pathway analysis and visualization,” Moleculer BioSystems, vol. 12, no. 2, pp. 477–479, 2016.

[23] G. Yu, L. G. Wang, and Y. Han, “ClusterProfiler: an R package for comparing biological themes among gene clusters,” OMICS, vol. 16, no. 5, pp. 284–287, 2012.

[24] J. Y. Xu, C. Zhang, X. Wang et al., “Integrative proteomic characterization of human lung adenocarcinoma,” Cell, vol. 182, no. 1, pp. 245–261.e17, 2020, e217.

[25] W. Li, L. Ye, Y. Chen, and P. Chen, “P3H4 is correlated with clinicopathological features and prognosis in bladder cancer,” World Journal of Surgical Oncology, vol. 16, no. 1, p. 206, 2018.

[26] A. E. Morgan, T. J. Davies, and M. T. Mc Auley, “The role of DNA methylation in ageing and cancer,” The Proceedings of the Nutrition Society, vol. 77, no. 4, pp. 412–422, 2018.
[27] L. A. Pikor, V. R. Ramnarine, S. Lam, and W. L. Lam, "Genetic alterations defining NSCLC subtypes and their therapeutic implications," *Lung Cancer*, vol. 82, no. 2, pp. 179–189, 2013.

[28] X. Ni, M. Zhuo, Z. Su et al., "Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 110, no. 52, pp. 21083–21088, 2013.

[29] Y. Duan, J. Haybaeck, and Z. Yang, "Therapeutic potential of PI3K/AKT/mTOR pathway in gastrointestinal stromal tumors: rationale and progress," *Cancers*, vol. 12, no. 10, p. 2972, 2020.

[30] C. Serrano and S. George, "Gastrointestinal stromal tumor: challenges and opportunities for a new decade," *Clinical Cancer Research*, vol. 26, no. 19, pp. 5078–5085, 2020.

[31] D. Ramchandani and V. Mittal, "Thrombospondin in tumor microenvironment," *Advances in Experimental Medicine and Biology*, vol. 1272, pp. 133–147, 2020.

[32] E. Koedoot, L. Wolters, M. Smid et al., "Differential reprogramming of breast cancer subtypes in 3D cultures and implications for sensitivity to targeted therapy," *Scientific Reports*, vol. 11, no. 1, p. 7259, 2021.